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Abstract: Bacteriophages (phages) or bacterial viruses have been proposed as natural antimicrobial
agents to fight against antibiotic-resistant bacteria associated with human infections. Enterococcus faecalis
is a gut commensal, which is occasionally found in the mouth and vaginal tract, and does not
usually cause clinical problems. However, it can spread to other areas of the body and cause
life-threatening infections, such as septicemia, endocarditis, or meningitis, in immunocompromised
hosts. Although E. faecalis phage cocktails are not commercially available within the EU or USA,
there is an accumulated evidence from in vitro and in vivo studies that have shown phage efficacy,
which supports the idea of applying phage therapy to overcome infections associated with E. faecalis.
In this review, we discuss the potency of bacteriophages in controlling E. faecalis, in both in vitro and
in vivo scenarios. E. faecalis associated bacteriophages were compared at the genome level and an
attempt was made to categorize phages with respect to their suitability for therapeutic application,
using orthocluster analysis. In addition, E. faecalis phages have been examined for the presence
of antibiotic-resistant genes, to ensure their safe use in clinical conditions. Finally, the domain
architecture of E. faecalis phage-encoded endolysins are discussed.
Keywords: phage therapy; E. faecalis; OrthoMCL
1. Introduction
Enterococcus is a genus of gram-positive non-spore-forming bacteria that typically inhabit the
gastrointestinal tract (GIT), which currently contains thirty five well-recognized species [1], including
Enterococcus faecalis. The enterococci possess a remarkable ability to adapt to different environments
and have a propensity to acquire antibiotic resistance, which has led to the emergence of multi-drug
resistant variants, across the genus [1]. E. faecalis is mainly described as a core commensal member of
the human gut, but it can also act as an opportunistic pathogen and translocate across the mucosal
barrier to cause systemic infections [2,3]. More than 90% of the bacterial isolates frequently recovered
from clinical specimens (blood, and other infectious site samples) are E. faecalis and E. faecium [4,5].
Life-threatening infections generally linked to E. faecalis include endocarditis, bacteremia, urinary
tract infections, meningitis, and root canal infections. In contrast, E. faecalis Symbioflor 1 strain
(Symbiopharm, Herborn, Germany) has been demonstrated to be a safe and effective probiotic and a
few other enterococcal strains have been used as starter cultures in the cheese industry [6]. However,
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the genus Enterococcus is not listed in the Qualified Presumption of Safety (QPS) of the European Food
Safety Authority, nor does it have a generally regarded as safe (GRAS) status [6]. Hence the continued
use of enterococci in traditional fermented foods and as probiotics, is controversial, because of their
association with human infections [7].
Antimicrobial resistance (AMR) causes 700,000 global deaths each year, and it is estimated that
it will rise to 10 million deaths by 2050 [7,8]. The high prevalence of Multi-Drug Resistant (MDR)
bacteria and inefficiency of available antibiotics to overcome infectious diseases, has inspired a search
for viable alternatives. Bacteriophages, also known as phages, and their associated cell wall lysing
enzymes (endolysins), have the potential to be useful tools to combat MDR pathogens [9–11].
Phages are prokaryotic viruses that have the ability to infect and replicate within their host
bacterial cell, and to subsequently lyse the cell, to release their progeny. Based on their replication
strategy, phages can undergo two different life cycles; the lytic (virulent) and the lysogenic (temperate).
Naturally virulent phages are suitable candidates for phage therapy, but temperate phages are not
as useful. However, genome engineering strategies can be applied to convert temperate phages to
virulent, for their effective use in phage therapy [12]. Phage therapy is described as the application of
phages to treat bacterial infections [13,14]. There are some indications that phages could be suitable
alternatives to combat Enterococcus-associated infections [2,15–18]. In this review, we focus on (i) phage
therapy to treat E. faecalis infections using in vitro and in vivo models; (ii) the genetic relationships
between currently isolated E. faecalis bacteriophages; (iii) identification of candidates suitable for phage
therapy; (iv) E. faecalis phages endolysins as alternative to phage therapy; and (v) conclusions and
recommendations for further development of E. faecalis phage therapy.
2. The Necessity of E. faecalis Phage Therapy
E. faecalis is one of the first colonizers of the human GIT and it plays a role in intestinal immune
development at the very early stages of life [19]. E. faecalis is a ubiquitous microorganism that possesses
the ability to survive and persist in a broad range of environments. In susceptible hosts, E. faecalis can
act as an opportunistic pathogen, causing severe infections, including urinary tract infections (UTIs),
endocarditis, bacteremia, catheter-related infections, wound infections, and intra-abdominal and pelvic
infections [1].
An important question is, what makes this bacterium an opportunistic pathogen and under what
circumstances? The key factors linked to the pathogenic role of E. faecalis in the GIT is its ability
to generate reactive oxygen species (ROS) and extracellular superoxide, which can cause genomic
instability and damage to the colonic DNA [20]. Opportunistic infection has been associated with the
production of virulence factors, adherence to Caco-2 and HEP-2 cells, capacity for biofilm formation
and resistance to antimicrobials [21–23]. Numerous virulence factors have been identified that are
associated with a wide range of E. faecalis infections; namely, aggregation substance (AS), adhesion to
collagen of E. faecalis (Ace), cell wall glycopeptides, gelatinase (GelE) and biofilm-associated Pili (Ebp),
Enterococcal fibronectin-binding protein A (EfbA), membrane metalloprotease (Eep), and biofilm
formation. AS is a pheromone-inducible plasmid-encoded cell surface protein, involved in bacterial
aggregation during conjugation, via binding to the enterococcal binding substance (EBS) [22–26].
There are three AS proteins (Asa1, Asc10, and Asp1), which belong to a family of surface adhesions
and are highly similar to each other. These factors are responsible for the initial adherence and biofilm
formation at infected sites [25,27]. Other important cell wall-associated virulence factors are pili and
fimbriae, which are anchored to the outer cell surface of the bacterium and aid the bacterium to adhere
to host cells. In E. faecalis, these are encoded by a three-gene locus (ebpABC), with an associated
enzyme sortase, srtC. This ebpABC locus has also been shown to encode proteins involved in biofilm
formation [24,28].
Other virulence factors such as Ace, a cell-wall anchored adhesion, plays a pivotal role in in vitro
adherence [27,29]. Similarly, EfbA, located on the outer cell membrane, confers adhesion to the host
glycoprotein fibronectin [30]. One more critical virulence factor is GelE, an extracellular zinc-metallo
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protease that contributes to the degradation of various host proteins, such as collagen, fibrinogen,
fibrin, and immune complement components C3 and C3a. Many of these factors associated with
virulence are also known to promote biofilm formation in E. faecalis, suggesting that biofilms are crucial
to development of severe infections [31].
In addition, E. faecalis is intrinsically resistant to numerous antibiotics, such as penicillin, ampicillin,
piperacillin, imipenem, and vancomycin—which have only bacteriostatic rather than bactericidal
effects [32]. Over the last decade vancomycin-resistant E. faecalis (VREF), together with the other
vancomycin-resistant enterococci (VRE), have generated much concern. In the context of a cumulative
mortality rate of 20–40% for infective endocarditis, generated by E. faecalis and E. faecium, E. faecalis
accounts for approximately 97% of cases [33]. In contrast to that, in leukemia patients, the VR E. faecium
is more prevalent, accounting for 84%, followed by E. faecalis accounting for 6% and the rest 10%
was occupied by all other Enterococcus sp. [34] and these percentages slightly varied in different
studies [35]. In addition, it has been reported that VR E. faecium was the leading cause of early
infection-related mortality in older (≥60 years) acute leukemia patients, who were receiving induction
chemotherapy [36]. Moreover, enterococcal bloodstream infections occurs frequently in patients with
acute leukemia, and causes significant morbidity and mortality (87% due to E. faecium, while only 13%
due to E. faecalis) [37]. However, the role of E. faecalis and E. faecium in colorectal cancer and other
diseases such as inflammatory bowel disease (IBD), remains unclear, and their involvement in colorectal
cancer is still under investigation [38]. It is presumed that it is the inefficient activity of β-lactams, as
well as the biofilm-forming ability of E. faecalis which makes these infections difficult to treat. Often,
combinations of antibiotic therapies are required for treatment of severe infections associated with
E. faecalis. However, even these antibiotic treatment options are limited, considering that 50% of
isolates exhibit a high-level of aminoglycoside resistance, mediated by aminoglycoside-modifying
enzymes, which eliminate the synergistic bactericidal effect, usually seen when a cell wall-active agent
is combined with an aminoglycoside [33,39].
3. Strategies for Obtaining E. faecalis Phages for Phage Therapy
There are several advantages associated with bacteriophages over antibiotics to treat bacterial
infections. For example, unlike antibiotics, bacteriophages are highly specific to their corresponding
target and, thus, do not perturb indigenous microbial communities [13,40–42]. Phages targeting
Enterococcus spp. have been isolated from various sources, like sewage, animal yard effluents, human
feces, urogenital secretions or by inducing chromosomally integrated prophages [17,43–46].
In general, plaque and spot assays are the methods applied by researchers to isolate phages, using
bacterial hosts of interest. In an attempt to increase the recovery of phages from environments where
they are scarce, a pre-enrichment step has been widely used, prior to plaque/spot assay. In the case of
E. faecalis, typically, vancomycin-resistant strains or other clinical isolates have been used for screening,
in order to realize the potential of phages as novel therapeutics [38,41].
Many factors can affect the process of phage isolation. For example, poor or invisible plaque
morphology, difficulty in obtaining confluency of bacterial lawns, poor enrichment of samples containing
very low numbers of phages, or sample availability [47]. Furthermore, bacterial host strains might adapt
to routine laboratory culturing practices resulting in changes to their cell physiology. Such genotypic
and phenotypic changes which occur during sub-culturing, can reduce the chances for the discovery
new phages. To overcome such hurdles, Purnell et al. [37], suggest the isolation of target bacterial hosts,
and their cognate bacteriophages, from the same sample, to achieve a higher success rate. Therefore, it is
advisable to obtain a fresh culture from the glycerol stock and avoid multiple sub-culturing and serial
broth-to-broth transfers, prior to phage isolation. In addition, bacteria can rapidly evolve to overcome
phage infection by means of spontaneous mutation, or by acquiring CRISPR-cas mediated adaptive
immunity, resulting in bacteriophage-insensitive mutants (BIMs) [48–50]. In addition, since multiple
bacterial strains can be involved in diseases, the application of phage cocktails are deemed to be more
appropriate over single-phage preparations, in therapeutic interventions [16].
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4. Orthocluster Analysis of E. faecalis Phages
On the 30 December 2018, fifty-four Enterococcus phage genome sequences were available
(http://millardlab.org/bioinformatics/bacteriophage-genomes/), of which 89% had E. faecalis and
11% had E. faecium as a target (Table S1). Usually, these phages infect both species at varying
efficiencies [16,17,51–54].
To determine the gene content relationship between these bacteriophages, a cluster analysis was
performed on the basis of the percentage of shared orthologous genes. For the orthocluster analysis,
the phage genomes were downloaded from the NCBI database, and potential Open Reading Frames
(ORFs) were predicted by Prodigal [55]. Identification of the bacteriophage protein Orthologous Groups
(OG, cluster of proteins from at least two phages) was performed, using orthoMCL [56]. OrthoMCL
phage clusters identified from this analysis were defined as “orthoclusters”. This analysis allowed the
identification of ten distinct and well-supported (100% bootstrap support) clusters of Enterococcus phage
genomes. Of the fifty-four Enterococcus phage genomes, fifty-two fell into one of the ten distinct clusters,
designated as orthoclusters I–V, VII, IX–X, as depicted in Figure 1. The remaining two phages used in
this analysis, did not cluster with any other phages. Therefore, we hypothesize that the phages EF62phi
and phiFL4, formed two different orthoclusters, V and VII, respectively. The distinct orthoclusters,
typically contain phages of the same family, with similar genome size, GC content and morphology.
The clustering was in good agreement with classical taxonomical phage families, as determined by the
morphology and genome analysis—virulent Myoviridae family—orthocluster II, virulent Siphoviridae
family—orthoclusters I, III, V, VII, IX, and X, temperate Siphoviridae family—orthoclusters IV and VIII,
and temperate Podoviridae family—orthocluster V, and virulent Podoviridae family—orthocluster VI.
With respect to phage therapy, orthoclusters comprising native virulent phages, are of immense
interest. Of the Enterococcus phages characterized to date, 77% are known to be virulent, and belong to
the orthoclusters I, II, III, IV, VI, IX, and X. Although temperate phages have less obvious usefulness
with respect to phage therapy, molecular mechanisms of phage conversion from temperate to virulent,
might make this possible.
Orthocluster I, which is supported by a bootstrap value of 1000, contains 19 phages belonging to
the Siphoviridae family. This orthocluster is particularly interesting as the phages differ significantly
from each other, in terms of their genome length and mean GC content, features which are conserved
among the other orthoclusters. The genome sizes range from ~17 kb to ~42 kb, and the mean GC content
varies from 17.35% to 36.7%. The suitability of these phages for phage therapy is questionable, as the
orthologous group 32, which belongs to orthocluster I, contains the putative metallo-beta-lactamase
gene, a gene related to antibiotic resistance (Figure 2) [57,58]. All phages harbor this gene, except for
EFRM31 and EFAP_1, within the orthocluster I. However, the functionality of this gene is currently
unknown. Further studies are warranted to evaluate these phages and their involvement in antibiotic
gene dissemination in the gut. In addition, gene editing tools could be applied to either delete or
inactivate the metallo-beta-lactamase gene, before considering therapeutic applications. A study by
Nezhad Fard et al. [59], demonstrated that the phage EFRM31 was efficient at transducing gentamicin
resistance to multiple enterococcal species. In fact, this was the first example of inter-species host range
generalized transduction, and thus, it did not support a role for such phages in therapeutic applications.
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Figure 1. Genomic comparison of Enterococcus phages. (A) Neighbor-joining tree based on the
percentage of shared orthologous genes (1000 bootstrap replicates); squares indicate the 10 phage
putative orthoclusters. (B) Dot plot comparison of amino acids identity among the 10 orthoclusters;
genes that share more than 40% homology were considered as being part of the same orthologous
group. The vertical axis shows phage clusters and phage IDs.
Interestingly, Orthocluster II incorporates all the Myoviridae phages described so far, which infect
E. faecalis. These phages can infect and proliferate in multiple strains of E. faecalis and E. faecium strains.
The size of the genomes ranged between ~130 kb to ~150 kb, and the mean GC content was estimated
to be 35.3% to 37.2%. These phages were related to SPO1-like viruses, such as the Staphylococcus phage
K, Listeria phage P100, and Lactobacillus phage LP65. Interestingly, no E. faecalis temperate phages
belonging to the Myoviridae family have ever been described [16,60].
Orthocluster III contains the most studied E. faecalis virulent phages from the Siphoviridae family
(genus Sap6virus). The size of the genomes ranged between ~53 kb to ~59 kb, and the mean GC
content was estimated to be 39% to 40%. These phages exhibited a broad host range and a high
level of efficiency in in vitro and in vivo studies, which have been discussed in more detail, later on.
Genome analysis did not reveal any putative virulence factors or antibiotic-resistant genes, and to
date no transduction potential has been described. Members of this orthocluster should, therefore, be
considered and studied with respect to their therapeutic potential [61,62].
The phages from Orthocluster IV were induced using norfloxacin and UV from bacteremia isolates
of the Enterococcus sp. These temperate phages belonged to the Siphoviridae family, with a genome size
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of 30–40 kb, and a mean GC content of 30%–40%. Currently, only virulent phages have been considered
as suitable candidates for phage therapy, but there is a possibility to convert these lysogenic phages to
virulent entities, which would allow us to investigate these phages in the context of phage therapy.
However, the use of genetically-modified phages, is not acceptable, for now [12]. Further inspection
of the orthocluster IV harboring temperate phages, revealed their ability to pack its bacterial host
DNA, a generalized transduction potential event observed in some other temperate phages, as well.
As a result, these phages are not suitable for phage therapy. It is unfortunate that on rare occasions
generalized transduction events have also been observed in some virulent phages [43].
The Podoviridae phage, EF62phi (~30 kb, mean GC content 32.7%) which forms the putative
orthocluster V, is a pseudotemperate linear bacteriophage identified in the genome of E. faecalis strain
62, isolated from a healthy Norwegian infant. EF62ph is the only pseudotemperate enterococcal
phage described to date. EF62ph is maintained in the bacterial genome by means of RepB and a
toxin–antitoxin system [63]. There have been no studies, so far, on pseudotemperate enterococcal
phages and their involvement in phage therapy.
Figure 2. Maximum likelihood phylogenetic analysis sequence relatedness of the Enterococcus faecalis
phage putative metallo-beta-lactamase gene (orthologous group 32); tree node labels represent
bootstrap values.
Orthocluster VI is comprised of the Podoviridae phages, of the genus Ahjdlikevirus. These phages
have been isolated from sewage, and infect both E. faecalis and E. faecium strains. The size of the
genomes range from ~17 kb to ~18 kb, and have a mean GC content of 33.2% to 34.6%. With no
evidence of antibiotic-resistance-associated genes or transduction potential, these phages should be
explored further for potential therapeutic applications [17,54,64].
The phage phiFL4A, which forms the putative orthocluster VII (Siphoviridae family, Phifelvirus
genus, 37 kb, mean GC content 37.8%) was induced from bacteremia isolates, using mitomycin C, in
the same study as that of the phages of orthocluster IV. This phage is also temperate and has the ability
of generalized transduction and, therefore, is not eligible for phage therapy [43].
Orhocluster VIII contains three temperate prophages and is part of the Siphoviridae family. phiEf11
was induced with mitomycin C from the root isolate E. faecalis TUSoD11 [65], EFC1 was induced with
mitomycin C from the raw milk isolate E. faecalis KBL101 [66] and vB_EfaS_IME197 was isolated from
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sewage. The size of the genomes range from ~40 kb to ~42 kb and the mean GC content from 34% to
35%. This group is particularly interesting from the point of view of phage therapy, as Ef11 phage have
been converted from temperate to virulent, followed by successful testing against E. faecalis. Therefore,
the temperate phages from this orthocluster opens the direction for a new type of E. faecalis phage
therapy, based on genetically engineered phages [67–69]
The phages that form orthocluster IX, EF1, and EF5, were previously annotated as part of the
Myoviridae family. However, our genome annotation using RASTtk and BLAST suggest that these two
virulent phages are part of the Siphoviridae family. By comparison with the other Siphoviridae virulent
E. faecalis phages, these two phages have a large genome of 141.996 kb, with a mean content GC of 31.9%.
Larger genomes are typical for Myoviridae family, which may be the reason for their previous attribution
in the database. No therapeutic studies have been performed using these phages and, therefore, their
potential role in phage therapy could not be predicted. Despite this, our genome analysis did not
reveal any genes that would hinder further research of these phages for therapeutic potential.
Phages VPE25 and VFW formed orthocluster X. They were isolated from sewage and shared 95%
homology at the nucleotide level. The size of the genomes of both phages was ~86 kb, with a mean GC
of 33.2%. VPE25 and VFW were obligate lytic and their isolation, using VR E. faecalis V583 as a host,
suggested them to be putative candidates for therapy [70].
Phages from each of the described orthocluster are now discussed in more details, with respect to
the published in vitro and in vivo phage therapy studies.
5. E. faecalis Phage Therapy in In Vitro Models
5.1. Biofilm Eradication
Various studies describe the ability of single phage or phage cocktails in the treatment of bacterial
biofilms. For example, biofilms formed by pathogenic bacteria Streptococcus mutants [71], E. coli [72],
Pseudomonas aeruginosa [73], Staphylococcus aureus [74], and E. faecalis [75], can be disrupted by phages.
Phage treatment is more efficient against biofilms, compared to conventional antibiotics, since, as the
phages infect the bacteria from the upper layer, upon replication they release a new virion progeny,
which subsequently attacks the bottom layer(s). As a result of this layer-by-layer mode of action,
the biofilms are effectively eradicated [75,76]. Microtiter plates are the most commonly used method
for studying biofilm formation, and to test the activity of antimicrobial compounds. More advanced
techniques like confocal microscopy can also be applied for the visualization of biofilm matrices, before
and after phage treatment [77]. Using this method, the efficiency of phage EFDG1 (orthocluster II) to
reduce two-week-old biofilms of E. faecalis V583 has been described [18]. The genetically-engineered
orthocluster VIII phage phiEf11 (phiEf11/phiFL1C(∆36)PnisA [67]), reduced the static biofilm of
E. faecalis strains JH2-2 (pMSP3535 nisR/K) and V583 (pMSP3535nisR/K), which had formed on
coverslips. After 24 and 48 h of incubation, a 10–100-fold decrease in viable cells (CFU/biofilm) was
observed [69].
5.2. Human Root Canal Model (In Vitro/Ex Vivo)
E. faecalis has been found, over time, to be more prevalent (24% to 77% of cases) in asymptomatic
and persistent endodontic infections [78,79]. The extreme survival ability and highly adaptive nature
of E. faecalis in harsh environments, allows the bacterium to cause persistent infections in root canals.
Furthermore, it can resist nutritional deprivation and invade dental tubules to form endodontic biofilms.
In this scenario, treatment with 2% chlorhexidine, combined with sodium hypochlorite, is generally
effective. However, a number of failures have been recorded in endodontic treatment, due to technical
difficulties associated with dental practices [78,80]. Therefore, the development of alternative strategies
are necessary to prevent such situations. In this regard, the efficacy of phage treatment has been
evaluated using an ex vivo two chamber bacterial leakage model of human teeth [18]. No turbidity
was observed in the obturated root canals, which were subjected to 108 PFU/mL of EFDG1 phage
Viruses 2019, 11, 366 8 of 18
(orthocluster II) irrigation and the results also indicated a 7-log reduction of bacterial leakage, from the
root apex, when compared to the control. In a similar study, Paisano et al. [81] showed that a phage
lysate of 2 × 108 PFU/mL was able to significantly inhibit E. faecalis in human dental roots inoculated for
6 days with a suspension of E. faecalis ATCC 29212 at the three different multiplicities of infection; 0.1,
1.0, and 10.0. Moreover, in the study of Tinoco et al [12]. extracted human dentin root segments were
cemented into a sealable double-chamber and inoculated for 7 days, with an overnight suspension of
either VR E. faecalis V583, or E. faecalis JH2-2, which is vancomycin sensitive, but resistant to fusidic
acid and rifampin. The treatment with genetically-engineered phage, phiEf11/phiFL1C (∆36)PnisA,
generated a reduction of 18% for the JH2-2-infected models, and by 99% for the V583-infected models.
These examples certainly strengthen the efficacy of phage therapy in the treatment of E. faecalis root
canal infections.
5.3. Fibrin Clot Model
Clots are gel-like clumps of blood that occurs when thrombin converts fibrinogen to fibrin,
a structural protein that assembles into a polymer [82]. An in vitro fibrin clot model has been successfully
used to test the role of antibiotics in the treatment of bacterial endocarditis [83], demonstrating the
in vitro clotting ability of bacterial strains Bacillus cereus [84], Staphylococcus aureus [85], E. faecalis [86],
and E. faecium [83,84]. Recently, the in vitro fibrin clot model has been used to demonstrate the efficacy of
individual phages and phage cocktails [16]. The authors spiked the plasma with vancomycin-resistant
and sensitive E. faecalis strains, and triggered the plasma coagulation with the addition of bovine
thrombin and CaCl2. The resultant clots were subjected to a 108 PFU/mL bacteriophage treatment.
Bacterial counts were significantly reduced by 3–6 logs, after treatment with phage(s) EFDG1 and
EFLK1 (orthocluster II).
5.4. E. faecalis Phages as Biocontrol Agents
Bacteriophages have long been recognized as effective biological entities in the control of undesired
foodborne bacteria. In 2007, a Listeria-specific bacteriophage preparation, Listex P100, obtained U.S.
FDA approval for use as a biopreservative, in ready-to-eat meat products (U.S. Food and Drug
Administration, 2007). In a recent study, phage Q69 has been shown to be effective against E. faecalis,
in a cheese model system. This phage significantly reduced E. faecalis numbers and subsequently
eliminated the accumulation of toxic biogenic amine tyramine, during cheese ripening [87].
6. E. faecalis Phage Therapy in In Vivo Models
To date, we are only aware of a single human study describing the phage treatment of E. faecalis
associated chronic prostatitis (Table 1). Three subjects were selected for phage therapy who had
failed to respond to antibiotic, auto-vaccine, and laser bio-stimulation treatments. During phage
treatment, 10 mL of bacterial phage lysate was rectally applied, twice daily, for 30 days. In all three
cases, the pathogen was eradicated, clinical symptoms abated, and early disease recurrence was not
observed [88].
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Table 1. Target infections, phage dosage, and outcomes in Enterococcus faecalis phage therapy in vivo models.
Disease
(Target Strain)
No (n) and
Type of Subjects Form and Dosage
Application Route and
Clinical Outcome Reference
Chronic bacterial prostatitis n = 3human male
Phage lysate
~107–109 PFU/mL
Rectal
Pathogen eradication,
Abatement of clinical symptoms
Lack of early disease recurrence
[88]
Infection
(EF14 VRE2)
n = 20;
BALB/c mice female
6 to 8 week old
CsCl;
1 × 1012 PFU/mL;
Intraperitoneal;
Significantly effective,
Efficiently rescued mice;
[89]
Bacteremia (VAN)
n = 5
BALB/c mice
1 month old
CsCl
3 × 108 PFU/mL
Intraperitoneal
100% survival 45 min after
bacterial challenge
50% of moribund mice rescued
after delayed phage
administration
[90]
Sepsis 002
n = 8
7 different dosage groups
BALB/c female mice
6 to 8 weeks old
PEG
3.9 × 109 PFU/mL or
0.2 mg endolysin
Intraperitoneal
60% survival at 30 min post
bacterial inoculation
40% survival at 4 h post
bacterial administration
[52]
E. faecalis challenge
n = 10
5 different dosage groups
BALB/c F
6 to 8 weeks old
CsCl
4 × 103, 4 × 104,
4 × 105, 4 × 106,
4 × 107 PFU/mouse
Intraperitoneal
Mice were protected from the
infection
[91]
Septic peritonitis
n = 15
4 groups
ICR(CD-1C)
Dialyzed phage lysate
2 × 108
Intraperitoneal
100% survival
No harmful effect on the
microbiome
[60]
E. faecalis challenge (VAN)
n = 5
4 different groups
BALB/c n female mice
6 to 8 weeks old
LysEF-P10 endolysin
1 µg, 5 µg, 10 µg
Intraperitoneal
Reduced E. faecalis colonization
Alleviated the gut microbiota
imbalance caused by VRE
[92]
VAN- experiment performed using vancomycin resistant E. faecalis; CsCl- Cesium chloride gradient purified phages; PEG- phage prepared by PEG precipitation.
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Other positive results obtained on treating infectious disease unresponsive to antibiotics, caused
by other bacteria, such as S. aureus, E. coli, Klebsiella, Proteus, Pseudomonas, and Enterobacter, support the
idea of using phage therapy against antibiotic-resistant E. faecalis [93]. All highlight the efficiency of
phages in disease resolution, and as future options for treating multi-drug-resistant bacterial infections.
Another example describes a life-threatening multi-drug-resistant pathogen Acinetobacter baumannii
infection, which was treated with an intravenous bacteriophage cocktail. This reversed the patient’s
clinical trajectory, cleared the A. baumannii infection, and restored the individual from a state of coma to
complete health [94]. More clinical scenarios like these will undoubtedly open new avenues for phages
or phage-derived enzybiotics as biotherapeutics, to combat situations where antibiotic treatments are
no longer viable.
6.1. Vertebrate Models
Meanwhile, some studies have shown the efficacy of phages, in vivo, against E. faecalis, using
mouse models (Table 1). An intraperitoneal application of phages, significantly rescued mice, when
deliberately challenged with the E. faecalis EF14 and E. faecalis VRE2 strains [95]. Similarly, another
study has showed that mice treated with different phage doses were protected from the VREF systemic
infection, and alleviated the gut microbial imbalance that occurred as a result of infection [91]. In another
study, a single dose of the lytic phage cocktail was effective in completely reversing a 100% mortality
in a septic peritonitis mouse model caused by VREF, and without causing any collateral damage to
the gut microbiome [60]. Furthermore, phage therapy has proven to be safe and effective in treating
E. faecalis-induced bacteremia [90] and sepsis [52], in mouse models.
6.2. Invertebrate Models
The larvae of wax moth Galleria mellonella has been used as a model system to examine pathogenesis
of many bacteria, such as S. aureus, P. aeruginosa, L. monocytogenes, Klebsiella pneumoniae, E. faecalis,
and E. faecium, and the fungi Candida albicans and Aspergillus fumigatus [96–100]. This model involves
monitoring G. mellonella caterpillars infected with bacterial culture, followed by the administration of a
test drug or saline solution as a negative control. A number of E. faecalis virulence gene factors have
been associated with larval mortality [101]. This method has been demonstrated as a suitable model for
studying E. faecalis-drug interaction, for example, studies have used distamycin, linezolid, rifampicin,
and extracts of Zingiber officinale [101–103]. The most significant advantage of this model is that it
allows a precise measurement of the inoculum and the quantity of the administrated drug, over time.
Not only are promising results obtained using this larval model, but it involves simple methodological
approaches. To date, there are no reports of phages treatment of E. faecalis in G. mellonella. However,
Yasmin et al. [43] infected G. mellonella with E. faecalis JH2-2 lysogenized by phiFL3A and phiFL3B
(orthocluster IV), and found that it increased the mortality of caterpillars. Conversely, some of the
other lysogens obtained in the same study, but with different phages, such as phiFL1B and phiFL2B
(orthocluster IV), and phiFL4A (putative orthocluster VII), did not show any death in the caterpillars,
when compared to the JH2-2 generic strain group. This G. mellonella model could be a valuable tool
to pre-screen the ability of phages in an in vivo scenario, before performing large scale animal trials.
In fact, the Galleria larval model has been used to examine the therapeutic potential of bacteriophages
against other bacterial pathogens, such as C. difficile [104], Burkholderia cepacia [105], Pseudomonas
aeruginosa [106], Escherichia coli, K. pneumoniae, Enterobacter cloacae [100], and Cronobacter sakazakii [107].
7. E. faecalis Phage Endolysins as Viable Alternatives for Phage Therapy
Endolysins, also termed phage lysins, have the ability to degrade the peptidoglycan layer of
bacterial cell walls, leading to cell death. These phage-derived enzymes allow the release of nascent
virions, following intracellular replication [108]. Endolysins possess a wide degree of killing activity,
which also makes them potential therapeutic agents. Considering the bottlenecks associated with the
production and purification of phages, to ensure the removal of host-derived endotoxins for therapeutic
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use, endolysin manufacture is a less arduous process, with a potentially similar outcome. Moreover,
with the advent of mass sequencing technologies and the availability of curated gene functional
databases, it is now possible to access the genomes of uncultured phages and their enigmatic gene
content, to develop potential lytic enzymes, without the necessity for phage isolation. In fact, an in
silico examination of uncultured phage genomes, revealed enormous diversity among endolysins [109].
With a varied host specificity and domain architecture, the development of robust novel antimicrobials
for future application are within our reach.
7.1. Domain Architecture of E. faecalis Phage Endolysins
Based on their muralytic activity, four types of phage endolysins have already been identified;
type I (lysozymes) and type II (transglycosidases); both of which act on the glycosidic bond linking
the amino sugars in the cell wall. Type III (amidases) and type IV (endopeptidases), both act on the
amide and peptide bonds of the oligopeptide cross-linking stems [110]. Endolysins typically consist
of an N-terminal catalytic domain targeting the peptidoglycan network, and a C-terminal cell wall
binding domain (termed as carbohydrate binding domain, CBD), which initializes the binding for
corresponding enzymatic action, against the specific substrate (Loessner, 2005). A comprehensive
in silico analysis on endolysin classes revealed that most (more than 74%) of the E. faecalis phage
endolysins have an LysM module as a part of their Cell Binding Domain (CBD), whereas the Enzyme
Catalytic Domain (ECD) consists of a glycosidase hydrolase (GH) module GH25 (the predominant
one 50–74%) and cysteine, and hsitidine-dependent amidohydrolase/peptidase (CHAP) (accounting
for less than 25%) (Oliveira et al. [111]). We identified a total of 54 putative and reference endolysin
sequences in E. faecalis phages (Figure 3). They were clustered into orthologous groups (OGs) using
OrthoMCL with default settings (Li et al. [57]). All but one (an endolysin associated with the phage
EF62phi) clustered into one of the four distinct orthologous groups (OG 22, OG 28, OG 78, and OG 236),
which mirrored the orthologous groups of their parental phages (Figures 2 and 3).
Figure 3. Maximum likelihood phylogenetic analysis sequence relatedness of E. faecalis phage endolysin
functional domains; tree node labels represent the bootstrap values; the sequence similarity between
functional domains is evidenced by using identical filling patterns; in blue—active domain; in
orange—biding in domain; each of the four orthologous group is represented by a different color;
Ef62phi could not be associated to any orthologous group.
One representative sequence was selected from each OG and subjected to HHMER [112] or
HHPRED [113] analysis, to determine the protein domain architecture. Proteins assigned to the same
OG often displayed the identical domain architectures, although a few exceptions were observed.
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In the case of ECD, three major domains—GH25, Amidase_2, and CHAP—were observed across the
four OGs, whereas in CBD, three domains—LysM, SH3, and PET-M23 (ZoocinA)—were identified
(Figure 3). This observation was consistent with the findings of Oliveira et al. [114].
7.2. Applications of E. faecalis Phage Endolysins
Of note, endolysins could also be used in combination with traditional antibiotics to treat
polyantibiotic-resistant bacterial pathogens. Many studies have shown the successful application of
phage endolysins, in treating multi-drug resistant bacterial infections caused by A. baumannii, S. aureus,
Methicillin resistance S. aureus (MRSA), E. coli, Proteus mirabilis, Klebsiella, Pseudomonas, Morganella,
Enterobacter, Enterococcus, and Salmonella [111]. A small number of studies have demonstrated the
in vivo efficacy of E. faecalis specific endolysins. One recent study evaluated endolysin LysEF-P10
to treat multi-drug resistant E. faecalis in a mouse model [92]. Here, a single intraperitoneal dose of
5 µg LysEF-P10 endolysin, was sufficient to eliminate the vancomycin resistant strain from the gut,
without causing any collateral damage to the gut communities. Another study described the use of the
endolysin IME-EF1, which protected 80% of mice challenged with a lethal dose of E. faecalis 002, and
significantly reduced bacterial proliferation in the blood [52]. Several studies have described the in vitro
antimicrobial action of E. faecalis endolysins. Heterologous expression of two endolysins Lys168 and
Lys170 derived from E. faecalis, displayed a promising activity against clinical isolates of exponentially
growing vancomycin-resistant and sensitive E. faecalis cultures, but failed to display a similar activity
against log phase cultures [62]. Lys170 contains a catalytic domain of the amidase-2 family, which
has an N-acetlymuramoyl-L-alanine amidase activity, while Lys168 was identified as being unique
among the enterococcal phage endolysins, and highly similar to the endolysin of S. aureus phage SAP6,
therefore, distantly related to all CHAP domain containing enterococcal endolysins [62]. In a follow-up
study, these authors used a domain shuffling approach, by fusing a peptidase M23 catalytic domain to
a cell-wall-binding domain of the native endolysin Lys170, to generate a bacteriolysin-like chimera,
designated as EC300, to improve its anti- E. faecalis activity [115]. A recent study highlighted the
advantage of using the phage endolysin IME-EFm5, over a narrow host range E. faecalis phage.
Interestingly, the endolysin of phage IME-EFm5, displayed lytic activity against almost all tested
strains [15]. Similarly, an expanded lytic activity of the E. faecalis bacteriophage φEF24C endolysin,
ORF9 has been observed when heterologously expressed in E. coli. Further analysis has revealed that
ORF9 belongs to the family of N-acetlymuramoyl-L-alanine amidases [44,116].
Antibacterial activity of a thermostable endolysin VD13 with an N-terminal CHAP domain has
been demonstrated in vitro, against E. faecalis, with no activity observed against E. faecium or any other
non-enterococcal strains tested [51]. In general, phage endolysins display a wider spectrum of activity
than their parental phage counterparts.
8. Conclusions
We conclude that phages could provide a viable alternative therapy to antibiotics in the fight
against E. faecalis infections. To date, only one clinical study has demonstrated the efficiency of
E. faecalis phages in a clinical setting. However, there are increased chances of developing a successful
phage therapy approach to an E. faecalis control, based on the in vitro and in vivo studies described
in this review. As far as we are aware, no current phage clinical trials are focused on E. faecalis, but
the outcomes of trials targeting other pathogens might be useful for the design of future E. faecalis
phage therapy.
One of the issues of phage therapy is the narrow host range of the phages. In the case of E. faecalis,
the diversity of phages showed in this review, based on the orthocluster identification, support the
idea of expanding the phage host range by creating phage cocktails with a broader host range. It is
unlikely that resistance will simultaneously occur for all virulent phages.
If this approach fails, there is the possibility of engineering temperate phages, as was done
successfully for the E. faecalis phage phiEf11. Moreover, even if phages fail in providing a
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therapy for E. faecalis, their endolysins might prove to be a suitable alternative in the fight against
E. faecalis-associated disease.
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